HB1476, the PLASMA Act, would amend the Medicare Part D manufacturer discount program to create a phased-in discount schedule for plasma-derived products. The bill defines plasma-derived products as biological products derived from human whole blood or plasma and applies the new rules to certain products marketed as of August 16, 2022. For these products, the discounted price used in the program would be set at a percentage of the negotiated price, with the percentage gradually declining over time rather than immediately reaching the standard discount level.
The phase-in differs depending on whether a beneficiary has already reached the annual out-of-pocket threshold for covered Part D drugs. For beneficiaries below that threshold, the discount would start at 99 percent in 2026 and step down to 90 percent by 2030 and later. For beneficiaries at or above the threshold, the phase-in continues further, reaching 85 percent in 2031 and 80 percent in 2032 and thereafter. The bill excludes certain drugs dispensed to low-income subsidy beneficiaries and certain small-manufacturer drugs from the phase-in.
The bill’s main legal effect would be to amend section 1860D-14C(g)(4) of the Social Security Act, changing how Medicare Part D calculates manufacturer discounts for a subset of specialty medicines. It would not broadly rewrite Medicare, but it would create a targeted exception for plasma-derived biological products within the manufacturer discount program, affecting manufacturers, Part D plans, pharmacies, and Medicare beneficiaries who use these therapies.
Available context shows no recorded votes and no committee transcript discussion, so there is no documented floor or committee sentiment to assess beyond the bill’s introduction and referral. Based on the bill text and title, the measure appears intended to support access to plasma-derived specialty medicines by easing the transition into the discount program, suggesting a generally favorable policy purpose for patients and manufacturers of these products.
The main point of contention likely concerns the cost and policy treatment of plasma-derived products within Medicare Part D. Supporters would likely emphasize access, continuity of supply, and the unique nature of plasma-based therapies, while critics could focus on the fiscal impact of reduced discounts, the creation of a special carve-out, and whether these products should be treated differently from other Part D drugs. The bill also draws a line between products and beneficiary categories, which could raise questions about fairness and program complexity.
HB1476 would amend the Social Security Act’s Medicare Part D manufacturer discount provisions, specifically section 1860D-14C(g)(4), to add a phased-in discount formula for plasma-derived biological products. It would affect how discounted prices are calculated for certain plasma-derived drugs marketed as of August 16, 2022, while preserving existing exclusions for low-income subsidy drugs and certain small-manufacturer drugs. The practical impact would be on Medicare Part D manufacturers, plans, and beneficiaries using plasma-derived therapies, with the federal program receiving smaller discounts on these products during the phase-in period than would otherwise apply.
There is no recorded vote or committee debate in the provided materials, so formal sentiment cannot be measured from legislative history. The bill’s title and structure indicate a supportive, access-oriented approach to specialty medicines, and the introduction by multiple House members suggests at least some bipartisan or cross-member interest. Overall, the available context points to a generally favorable posture toward the bill, especially from stakeholders concerned with patient access to plasma-derived treatments.
The likely contention centers on whether plasma-derived products should receive a special phased-in treatment under Medicare Part D. Supporters are likely to argue that these therapies are unique, medically important, and should not face immediate full discount obligations that could affect access or supply. Opponents or skeptics may question the revenue impact on the Medicare program, the fairness of carving out one class of drugs, and the added complexity of creating different discount schedules based on product type and beneficiary status. No specific objections are documented in the provided committee or vote history.